Notice for avelumab (Merck Healthcare Pty Ltd)
Active ingredients
avelumab
Sponsor
Date of review outcome
Lapse date
Type
Priority Review
Indication
For the first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) whose disease has not progressed with first-line platinum-based induction chemotherapy
Therapeutic area
Oncology